Introduction: Muscle atrophy, commonly triggered by glucocorticoids such as dexamethasone (DEX), involves increased protein degradation via the ubiquitin–proteasome system. Recent findings suggest ...

Muscle atrophy is relatively common among patients with ankylosing spondylitis and is linked to disease duration, education levels, and inflammatory markers.

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with fat, experts say.

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

Researchers have taken preliminary steps toward treating a devastating neurodevelopmental disorder, spinal muscular atrophy, with a genetic therapy delivered in the womb, before the worst damage ...

The flexor carpi ulnaris [FCU] fascia and muscle overlying the ulnar nerve was released. 1 cm of the medial intermuscular septum was also excised to provide a path for the ulnar nerve from posterior ...

We present a sensor toward wearable monitoring of muscle atrophy with improved stretching capabilities and sensing resolution for practical implementation. The operation relies on our previously ...

Caleb Kasner and his brother Duncan Kasner move around a little differently than average kids. The two brothers have Duchenne muscular dystrophy — a rare, inherited muscle-wasting disorder that ...

Optic nerve atrophy (ONA) is the result of various pathologies of the visual organ, in which the corresponding nerve is damaged. The optic nerve transmits visual signals from the retina to the brain, ...

Researchers reported what they called the first evidence that a spine-stimulating implant might aid neurodegenerative diseases like spinal muscle atrophy.

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

Late-stage trial data for Roche’s drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy.